CD22 Recombinant Antibody [hL22 (Epratuzumab) ] (OAAV00410)

This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques.

Reconstitution & Storage Instructions Western Blotting/Immunoblotting (WB/IB) Protocol Immunohistochemistry (IHC) Protocol Immunocytochemistry (ICC) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Blocking Peptide Competition Protocol (BPCP) Immunoprecipitation (IP) Protocol Antibody Array (AA) Protocol Reconstitution & Storage Instructions Reconstitution & Storage Instructions Western Blotting/Immunoblotting (WB/IB) Protocol Western Blotting/Immunoblotting (WB/IB) Protocol Immunohistochemistry (IHC) Protocol Immunohistochemistry (IHC) Protocol Immunocytochemistry (ICC) Protocol Immunocytochemistry (ICC) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Blocking Peptide Competition Protocol (BPCP) Blocking Peptide Competition Protocol (BPCP) Immunoprecipitation (IP) Protocol Immunoprecipitation (IP) Protocol Antibody Array (AA) Protocol Antibody Array (AA) Protocol

OAAV00429 reacts positively to melanoma cell lines with high GM2 expression (M14; M24), and shows no binding to normal cell types or cell lines M15 or M25 which have low GM2 expression and high GM3 expression. This specificity can be confirmed by ELISA and TLC immunostaining by testing a variety of gangliosides and neutral glycolipids. OAAV00429 is able to lyse cells from the M14 melanoma cell line (which has high GM2 expression) in the presence of human or rabbit complement, but not in the absence of complement - this was shown by a [51Cr] release assay. Biotinylated OAAV00429 has been used for IHC of acetone-fixed sections of tumor tissue in an avidin-biotin complex immunoperoxidase system. Statistically significant positive staining (determined by Fisher's exact test) was displayed with melanoma, colon carcinoma and ovary carcinoma tumor tissues. Staining has also be observed with breast carcinoma, prostate carcinoma and kidney carcinoma.

OAAV00429 binds specifically to GM2 ganglioside; this antibody shows no reactivity towards GM1, GM3, GD2 or normal tissues- the OAAV00429 epitope contains both a GalNAc and sialic acid bound to lactose. Ganglioside GM2 (GalNAc-beta-1-4 (NeuNAca2-3) Gal-beta-1-4Glc-beta-1ceramide) is a glycosphingolipid present on the cell surface and a major tumor-differentiation antigen in human melanoma and hepatoma.

This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques.